Furthermore, co-treatment of KU-55,933 or the PARP inhibitor olaparib with doxorubicin synergistically inhibited the proliferation of SIRT6-overexpressing U2OS and KHOS/NP osteosarcoma cells (Fig. 7a and b). Here, SIRT6 is linked to osteosarcoma.